US Stock MarketDetailed Quotes

LEXX Lexaria Bioscience

Watchlist
  • 3.0000
  • -0.4900-14.04%
Close May 2 16:00 ET
  • 2.9500
  • -0.0500-1.67%
Post 17:47 ET
38.66MMarket Cap-4477P/E (TTM)

About Lexaria Bioscience Company

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Company Profile

SymbolLEXX
Company NameLexaria Bioscience
Listing DateJan 12, 2021
Founded2004
CEOMr. Christopher Bunka
MarketNASDAQ
Employees5
Securities TypeOrdinary Shares
Fiscal Year Ends08-31
Address740 McCurdy Road,Suite 100
CityKelowna
ProvinceBritish Columbia
CountryCanada
Zip CodeV1X 2P7
Phone1-250-765-6424

Company Executives

  • Name
  • Position
  • Salary
  • Christopher Bunka
  • Chairman of the Board, Chief Executive Officer and Principal Financial Officer
  • 291.19K
  • Nelson Cabatuan
  • Chief Financial Officer
  • --
  • John M. Docherty
  • President, Principal Executive Officer and Director
  • 290.47K
  • Nicholas W. Baxter
  • Independent Director
  • 80.75K
  • William McKechnie
  • Independent Director
  • 72.04K
  • Albert L. Reese, Jr
  • Independent Director
  • 54.78K
  • Dr. Catherine C. Turkel
  • Independent Director
  • 48.92K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg